亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药-B

已收盘 07-25 16:08:27

27.050

-1.050

-3.74%

最高28.200	最低26.900	成交量112.41万
今开28.200	昨收28.100	日振幅4.63%
总市值85.11亿	流通市值85.11亿	总股本3.15亿
成交额3,066万	换手率0.36%	流通股本3.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药-B","latestPrice":27.05,"timestamp":1721894907035,"preClose":28.1,"halted":0,"volume":1124101,"delay":0,"floatShares":314654405,"shares":314654405,"eps":-3.5466104,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.05,"latestTime":"07-25 16:08:27","open":28.2,"high":28.2,"low":26.9,"amount":30664952,"amplitude":0.046263,"askPrice":27.05,"askSize":700,"bidPrice":26.95,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-3.546610439220828,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721957400000},"adr":0,"listingDate":1572192000000,"adjPreClose":28.1,"openAndCloseTimeList":[[1721871000000,1721880000000],[1721883600000,1721894400000]],"volumeRatio":1.300092,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855/tweets","defaultTab":"tweets","newsList":[{"id":"2452473449","title":"亚盛医药-B07月19日遭主力抛售129万元 环比增加138.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452473449","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452473449?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:15","pubTimestamp":1721376944,"startTime":"0","endTime":"0","summary":"07月19日, 亚盛医药-B股价跌3.90%，报收28.30元，成交金额2446万元，换手率0.27%，振幅4.92%，量比0.59。亚盛医药-B今日主力资金净流出129万元，连续3日净流出，上一交易日主力净流出54万元，今日环比增加138.89%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为100.00%，平均跌幅为2.94%。该股近5个交易日上涨1.44%，主力资金累计净流入83万元；近20日主力资金累计净流入4355万元，其中净流入天数为14日。该股主力净额占比0.01%，港股市场排名2418/2647。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407191616249f6a63fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407191616249f6a63fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2452852371","title":"【券商聚焦】中信建投首予亚盛医药(06855)“买入”评级 指重磅BIC潜力产品带动下营收有望持续高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2452852371","media":"金吾资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452852371?lang=zh_cn&edition=full","pubTime":"2024-07-17 15:11","pubTimestamp":1721200297,"startTime":"0","endTime":"0","summary":"公司将于协议签署后收到1亿美元的选择权付款，并有资格获得最高约12亿美元的选择权行使费以及额外的潜在里程碑付款。该行指，公司已在血癌和实体瘤等领域搭建多个产品管线，在重磅BIC潜力产品的带动下未来营收有望持续保持高增长。根据DCF估值模型，公司合理估值为103.63亿港元，对应目标价32.90港元，首次覆盖，给予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071715121095cd23ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071715121095cd23ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","09939"],"gpt_icon":0},{"id":"2451825959","title":"亚盛医药-B(06855)上涨5.01%，报29.35元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451825959","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451825959?lang=zh_cn&edition=full","pubTime":"2024-07-16 15:10","pubTimestamp":1721113851,"startTime":"0","endTime":"0","summary":"7月16日，亚盛医药-B(06855)盘中上涨5.01%，截至15:10，报29.35元/股，成交5384.14万元。亚盛医药集团是一家专注于肿瘤、乙肝及与衰老相关疾病治疗领域的创新药物开发的生物医药企业，拥有自主构建的蛋白-蛋白相互作用靶向药物设计平台，并已建立9个已进入临床开发阶段的1类小分子新药产品管线。公司的核心产品奥雷巴替尼已在中国获批上市，正在全球范围内进行40多项临床试验，且已有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定，2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。截至2023年年报，亚盛医药-B营业总收入2.22亿元、净利润-9.26亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/16151041592137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","159938","06855","09939","BK1515"],"gpt_icon":0},{"id":"2451895962","title":"亚盛医药－Ｂ(06855)股价上升5.009%，现价港币$29.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2451895962","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451895962?lang=zh_cn&edition=full","pubTime":"2024-07-16 15:10","pubTimestamp":1721113800,"startTime":"0","endTime":"0","summary":"[上升股]亚盛医药－Ｂ(06855) 股价在下午03:10比前收市价上升5.009%，现股价为港币$29.35。至目前为止，今日最高价为$29.35，而最低价为$27.95。总成交量为185.846万股，总成交金额为港币$5.366千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407161621/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","06855","BK1515","159938","BK1161","09939"],"gpt_icon":0},{"id":"2451834954","title":"亚盛医药涨超3%，恒生医药ETF午后溢价","url":"https://stock-news.laohu8.com/highlight/detail?id=2451834954","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451834954?lang=zh_cn&edition=full","pubTime":"2024-07-16 14:55","pubTimestamp":1721112904,"startTime":"0","endTime":"0","summary":"2024年7月16日，港股医药板块盘中持续小幅震荡，亚盛医药、再鼎医药、荣昌生物等涨幅居前，乐普生物、药明合联等下挫。恒生医药ETF午后溢价走高。在近期震荡调整阶段，恒生医药ETF溢价情况持续，在近10个交易日中有9日获得资金净流入。以上内容与数据，与界面有连云频道立场无关，不构成投资建议。据此操作，风险自担。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161531279f546636&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161531279f546636&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","06855","BK1574","BK1515"],"gpt_icon":0},{"id":"2451398715","title":"港股异动 | 亚盛医药-B(06855)早盘涨超4% 耐立克澳门获批上市 此前收到武田1亿美元选择权付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2451398715","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451398715?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:20","pubTimestamp":1721096442,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B(06855)早盘涨超4%，截至发稿，涨3.4%，报28.9港元，成交额2073.53万港元。消息面上，7月8日，亚盛医药宣布其核心品种第三代BCR-ABL抑制剂耐立克(奥雷巴替尼)正式在中国澳门获批上市。集团表示，耐立克获国家“重大新药创制”专项支持，是国家药品监督管理局批准上市的首个第三代BCR-ABL抑制剂，在中国的商业化推广由亚盛医药和信达生物共同负责。值得注意的是，上月，亚盛医药与武田制药就公司耐立克签署了一项总价达13亿美元的具有“高首付、高里程碑、高分成”特点的独家选择权协议。仅过19天，7月2日亚盛医药便收到了来自武田的1亿美元选择权付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","07226","159938","BK1515","06855","BK1574","HSTECH","HSCEI","YANG","BK1161"],"gpt_icon":0},{"id":"2451131726","title":"亚盛医药-B07月15日主力资金流入227万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2451131726","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451131726?lang=zh_cn&edition=full","pubTime":"2024-07-15 16:15","pubTimestamp":1721031355,"startTime":"0","endTime":"0","summary":"07月15日, 亚盛医药-B股价涨0.54%，报收27.95元，成交金额4205万元，换手率0.48%，振幅3.60%，量比1.50。亚盛医药-B今日主力资金净流入227万元，连续3日净流入，上一交易日主力净流入316万元，今日环比减少28.16%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为60.00%，平均涨幅为3.28%。该股近5个交易日上涨3.13%，主力资金累计净流入1974万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入6221万元，其中净流入天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151616239f4da48a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151616239f4da48a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1574","BK1515","BK1161","06855"],"gpt_icon":0},{"id":"2450766805","title":"亚盛医药－Ｂ(06855)出现大手买入23.59万股，成交价$27.7，涉资653.443万","url":"https://stock-news.laohu8.com/highlight/detail?id=2450766805","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450766805?lang=zh_cn&edition=full","pubTime":"2024-07-11 11:19","pubTimestamp":1720667940,"startTime":"0","endTime":"0","summary":"[大手成交]亚盛医药－Ｂ(06855)在上午11:19出现大手买入，成交量为23.59万，成交价为港币$27.7，涉资653.443万。至目前为止，股价升1.859%，今日最高价为$27.8，而最低价为$26.9，总成交量为115.39万股，总成交金额港币$3.178千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2407113533/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","159938","BK1515","09939","06855"],"gpt_icon":0},{"id":"2449708592","title":"亚盛医药：耐立克在中国澳门获批上市，治疗CML-CP和CML-AP成年患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2449708592","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449708592?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:30","pubTimestamp":1720427445,"startTime":"0","endTime":"0","summary":"快讯正文【亚盛医药原创1类新药奥雷巴替尼在澳门获批上市】亚盛医药7月8日宣布，其原创1类新药奥雷巴替尼在中国澳门特别行政区获批上市。此次获批的适应症包括治疗对酪氨酸激酶抑制剂（TKI）耐药并伴有T315I突变的慢性髓细胞白血病（CML）慢性期和加速期的成年患者，以及对一代和二代TKI耐药和/或不耐受的CML-CP成年患者。耐立克是国家药监局批准的首个第三代BCR-ABL抑制剂，对BCR-ABL及多种突变体有显著效果，已纳入美国国家综合癌症网络CML治疗指南。该药物在中国的商业化推广由亚盛医药和信达生物共同负责。下载和讯APP查看快讯，体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407082107529f1ecd16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407082107529f1ecd16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2449168347","title":"多重利好持续发酵，亚盛医药-B(06855)估值新增量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2449168347","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449168347?lang=zh_cn&edition=full","pubTime":"2024-07-08 10:26","pubTimestamp":1720405562,"startTime":"0","endTime":"0","summary":"据智通财经APP了解，7月8日，亚盛医药-B宣布其核心品种第三代BCR-ABL抑制剂耐立克正式在中国澳门获批上市。对于亚盛医药来说，7月仅过8天但已是双喜临门。上月，亚盛医药与武田制药就公司耐立克签署了一项总价达13亿美元的具有“高首付、高里程碑、高分成”特点的独家选择权协议。仅过19天，7月2日亚盛医药便收到了来自武田的1亿美元选择权付款。但目前港股市场上，亚盛医药的潜在价值显然还未得到合理体现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","06855","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2448209450","title":"亚盛医药(06855.HK)已向Takeda收取1亿美元独家选择权付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2448209450","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448209450?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:45","pubTimestamp":1720053900,"startTime":"0","endTime":"0","summary":"亚盛医药公布，根据与Takeda的耐立克独家选择权协议，已于7月2日收取Takeda的1亿美元选择权付款。耐立克为一种口服、潜在同类最佳的第三代BCR-ABL TKI，目前正在开发用于治疗CML及其他血液癌症。根据独家选择权协议，允许亚盛收取1亿美元的选择权付款，且倘Takeda行使选择权以许可耐立克，则让亚盛有资格获得最高约12亿美元的选择权行使费及额外的潜在里程碑付款，以及年销售额两位数百分比的销售分成。沽空资料截至 2024-07-03 16:25。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201214152343086_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201214152343086_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361234/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06855","BK1574","09939","159938","BK1161","BK1515"],"gpt_icon":0},{"id":"2448450176","title":"亚盛医药宣布已收到武田1亿美元选择权付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2448450176","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448450176?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:39","pubTimestamp":1720053540,"startTime":"0","endTime":"0","summary":"2024年6月14日，亚盛医药宣布与武田签署了独家选择权协议，授予武田独家选择权以就耐立克签署独家许可协议。根据该独家选择权协议条款，亚盛医药可收取1亿美元的选择权付款，并将有资格获得最高约12亿美元的选择权行使费和额外的潜在里程碑付款，以及年销售额两位数百分比的销售分成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4454675_ZH54675_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CDE","BK1161","BK1574","06855","BK4017"],"gpt_icon":0},{"id":"2448451383","title":"亚盛医药-B(06855)：根据与Takeda订立的独家选择权协议已收取的选择权付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2448451383","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448451383?lang=zh_cn&edition=full","pubTime":"2024-07-04 07:22","pubTimestamp":1720048927,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，内容有关公司、香港亚盛、广州亚盛、苏州亚盛及Takeda Pharmaceuticals International AG 订立独家选择权协议。独家选择权协议允许亚盛收取1亿美元的选择权付款，且倘 Takeda行使选择权以许可耐立克 ，则让亚盛有资格获得最高约12亿美元的选择权行使费及额外的潜在里程碑付款，以及年销售额两位数百分比的销售分成。公司董事会欣然宣布，亚盛已于2024年7月2日收取独家选择权协议条款允许的该选择权付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","06855","BK1574","BK1161","09939","159938"],"gpt_icon":0},{"id":"2448123659","title":"亚盛医药-B(06855)上涨5.29%，报26.85元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448123659","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448123659?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:09","pubTimestamp":1719983378,"startTime":"0","endTime":"0","summary":"7月3日，亚盛医药-B盘中上涨5.29%，截至13:09，报26.85元/股，成交2881.56万元。亚盛医药集团是一家专注于肿瘤、乙肝及与衰老相关疾病治疗领域的创新药物开发的生物医药企业，拥有自主构建的蛋白-蛋白相互作用靶向药物设计平台，并已建立9个已进入临床开发阶段的1类小分子新药产品管线。截至2023年年报，亚盛医药-B营业总收入2.22亿元、净利润-9.26亿元。7月2日，国元国际控股维持买入评级,目标价34.15港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/03130941343248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1515","BK1574","06855","09939","159938"],"gpt_icon":0},{"id":"2448355125","title":"亚盛医药-B盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448355125","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448355125?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:09","pubTimestamp":1719983373,"startTime":"0","endTime":"0","summary":"2024年07月03日下午盘13时09分，亚盛医药-B股票出现波动，股价快速上涨5.10%。截至发稿，该股报26.800港元/股，成交量109.87万股，换手率0.35%，振幅5.29%。亚盛医药-B股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，东曜药业-B、荃信生物-B、永泰生物-B涨幅较大，振幅较大的相关个股有盛禾生物-B、药明巨诺-B、方达控股，振幅分别为19.28%、17.46%、8.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703130933aef7b3b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703130933aef7b3b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","06855","BK1574","BK1161","09939"],"gpt_icon":0},{"id":"2448123274","title":"亚盛医药－Ｂ(06855)股价上升5.098%，现价港币$26.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2448123274","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448123274?lang=zh_cn&edition=full","pubTime":"2024-07-03 13:09","pubTimestamp":1719983340,"startTime":"0","endTime":"0","summary":"[上升股]亚盛医药－Ｂ(06855) 股价在下午01:09比前收市价上升5.098%，现股价为港币$26.8。至目前为止，今日最高价为$26.8，而最低价为$25.45。总成交量为108.26万股，总成交金额为港币$2.834千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407032510/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","BK1515","BK1161","159938","06855","BK1574"],"gpt_icon":0},{"id":"2448184634","title":"亚盛医药-B07月02日主力资金流入97万元 连续7日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448184634","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448184634?lang=zh_cn&edition=full","pubTime":"2024-07-02 16:15","pubTimestamp":1719908157,"startTime":"0","endTime":"0","summary":"07月02日, 亚盛医药-B股价跌0.20%，报收25.50元，成交金额2062万元，换手率0.26%，振幅2.94%，量比0.71。亚盛医药-B今日主力资金净流入97万元，连续7日净流入，上一交易日主力净流入292万元，今日环比减少66.78%。该股近5个交易日上涨1.60%，主力资金累计净流入736万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入3923万元，其中净流入天数为15日。该股主力净额占比0.01%，港股市场排名214/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021616139ef317f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021616139ef317f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2446365204","title":"亚盛医药(6855.HK)：三箭齐发 海外进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2446365204","media":"西南证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446365204?lang=zh_cn&edition=full","pubTime":"2024-06-26 18:41","pubTimestamp":1719398507,"startTime":"0","endTime":"0","summary":"事件：6月21 日，亚盛医药宣布已收到武田7500万美元股权投资款项。亚盛医药三箭齐发，耐立克授权、收到股权投资并计划赴美上市。将奥雷巴替尼除中国和其他一些地区之外的全球权利在全球范围内进行许可，亚盛医药在协议签署后将收到1 亿美元的选择权付款，并有资格获得最高约12 亿美元的选择权行使费和额外的潜在里程碑付款，以及基于年度销售额提成的双位数比例特许权使用费。APG-2575 国际化进程提速，多项适应症进入Ⅲ期临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261841499f677df9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261841499f677df9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","06855","09939","BK1574"],"gpt_icon":0},{"id":"2446607355","title":"亚盛医药-B06月26日获主力加仓81万元 环比增加350.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446607355","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446607355?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:15","pubTimestamp":1719389725,"startTime":"0","endTime":"0","summary":"06月26日, 亚盛医药-B股价涨0.20%，报收25.35元，成交金额1132万元，换手率0.14%，振幅2.17%，量比0.25。亚盛医药-B今日主力资金净流入81万元，连续4日净流入，上一交易日主力净流入18万元，今日环比增加350.00%。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为66.67%，平均涨幅为3.61%。该股近5个交易日下跌3.60%，主力资金累计净流入704万元；近20日主力资金累计净流入2583万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062616154295d98ce1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062616154295d98ce1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1574","09939","BK1161","BK1515"],"gpt_icon":0},{"id":"2446899483","title":"亚盛医药-B06月25日主力资金流入18万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2446899483","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446899483?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:16","pubTimestamp":1719303413,"startTime":"0","endTime":"0","summary":"06月25日, 亚盛医药-B股价涨1.00%，报收25.30元，成交金额3757万元，换手率0.47%，振幅4.79%，量比0.67。亚盛医药-B今日主力资金净流入18万元，连续3日净流入，上一交易日主力净流入498万元，今日环比减少96.39%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为60.00%，平均涨幅为3.28%。该股近5个交易日下跌4.54%，主力资金累计净流入849万元；近20日主力资金累计净流入2353万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406251617269f631967&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406251617269f631967&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","BK1515","BK1574","06855"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":-0.0507},{"period":"1month","weight":0.1218},{"period":"3month","weight":0.6243},{"period":"6month","weight":0.166},{"period":"1year","weight":0.2379},{"period":"ytd","weight":0.0293}],"compareEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0398},{"period":"3month","weight":0.0015},{"period":"6month","weight":0.0852},{"period":"1year","weight":-0.1093},{"period":"ytd","weight":0.0155}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。该公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。该公司的主要产品包括下一代激酶抑制剂HQP1351，细胞凋亡靶向药物APG-1252、 APG2575、APG-115等。该公司于国内市场及美国等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.061697},{"month":2,"riseRate":0.2,"avgChangeRate":-0.06377},{"month":3,"riseRate":0,"avgChangeRate":-0.152214},{"month":4,"riseRate":0.8,"avgChangeRate":0.111517},{"month":5,"riseRate":0.4,"avgChangeRate":0.061168},{"month":6,"riseRate":0.8,"avgChangeRate":0.262196},{"month":7,"riseRate":0.4,"avgChangeRate":-0.075187},{"month":8,"riseRate":0.75,"avgChangeRate":-0.014666},{"month":9,"riseRate":0,"avgChangeRate":-0.167512},{"month":10,"riseRate":0.5,"avgChangeRate":0.082137},{"month":11,"riseRate":0.6,"avgChangeRate":0.093711},{"month":12,"riseRate":0.6,"avgChangeRate":0.09133}],"exchange":"SEHK","name":"亚盛医药-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药-B,06855,亚盛医药-B股票,亚盛医药-B股票老虎,亚盛医药-B股票老虎国际,亚盛医药-B行情,亚盛医药-B股票行情,亚盛医药-B股价,亚盛医药-B股市,亚盛医药-B股票价格,亚盛医药-B股票交易,亚盛医药-B股票购买,亚盛医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}